When PS1 siRNA is delivered, it can synergistically impact the therapeutic efficacy of existing immunomodulating agents in HGSC and pancreatic ductal adenocarcinoma tumors, leading to induction of potent tumor-antigen-specific immune responses. Here, PSEN1 is linked to neoplasm.